NCT04145440: A reported trial by HI-Bio, A Biogen Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04145440 |
|---|---|
| Title | A Phase Ib/IIa, Open-Label, Multicenter Clinical Trial to Assess Safety and Efficacy of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (aMN) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 15, 2019 |
| Completion date | Jan. 19, 2022 |
| Required reporting date | Jan. 19, 2025, midnight |
| Actual reporting date | Nov. 20, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |